Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users.
Injection drug users represent a major vector of human immunodeficiency virus (HIV) infection in the nation's inner cities, and are an important population for harm reduction treatment interventions to target. However, there has been relatively little research examining the specific contribution of the multiple factors contributing to cognitive functioning among injection drug users that may affect engagement in, and response to, addiction and HIV-related interventions. The current study examined the independent contributions to neuropsychological (NP) test performance of premorbid educational attainment, medical and psychiatric history, long- and short-term drug use, assessed by laboratory, observation, and self-report measures, and HIV disease, assessed by plasma HIV-1 RNA viral load and CD4+ count, in a sample of 90 HIV-positive injection drug users dually addicted to heroin and cocaine. Fully 88% of the sample showed evidence of impairment (>1 standard deviation below the population mean) on an NP test battery selected to assess processes associated with successful engagement in the treatment of substance abuse and HIV, such as learning and memory of verbal information, capacity to solve new problems and deal with more than one stimulus at a time, visual-motor coordination, and visual tracking and cognitive flexibility. In addition to drug use, independent predictors of NP test performance were HIV viral load, educational attainment, and premorbid medical and psychiatric problems. Findings underscore the multiplicity of factors that contribute to cognitive impairment in HIV-positive drug-abusing individuals in addition to drug use. Clinical implications are discussed.
Yale University School of Medicine, Department of Psychiatry, New Haven, Connecticut 06519, USA. arthur.margolin@yale.edu
Arthur
A
Margolin
S Kelly
SK
Avants
Lara A
LA
Warburton
Keith A
KA
Hawkins
D000328:Adult; D018791:CD4 Lymphocyte Count; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology*; D004522:Educational Status; D005260:Female; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D009483:Neuropsychological Tests; D012367:RNA, Viral / Q000097:blood; D012044:Regression Analysis; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000534:rehabilitation; D019562:Viral Load
D012367:RNA, Viral; D008691:Methadone